A detailed history of Wells Fargo & Company transactions in Cv Rx, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 4,779 shares of CVRX stock, worth $64,516. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,779
Previous 4,941 3.28%
Holding current value
$64,516
Previous $59,000 28.81%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$7.15 - $12.37 $1,158 - $2,003
-162 Reduced 3.28%
4,779 $42,000
Q2 2024

Aug 13, 2024

BUY
$6.49 - $19.2 $5,269 - $15,590
812 Added 19.67%
4,941 $59,000
Q1 2024

May 10, 2024

BUY
$17.99 - $30.49 $8,131 - $13,781
452 Added 12.29%
4,129 $75,000
Q4 2023

Feb 09, 2024

BUY
$11.67 - $33.01 $6,196 - $17,528
531 Added 16.88%
3,677 $115,000
Q3 2023

Nov 13, 2023

SELL
$13.56 - $18.47 $20,055 - $27,317
-1,479 Reduced 31.98%
3,146 $47,000
Q2 2023

Aug 15, 2023

BUY
$8.57 - $15.44 $38,667 - $69,665
4,512 Added 3992.92%
4,625 $71,000
Q1 2023

May 12, 2023

BUY
$7.08 - $19.4 $14 - $38
2 Added 1.8%
113 $1,000
Q4 2022

Feb 13, 2023

BUY
$8.94 - $18.35 $17 - $36
2 Added 1.83%
111 $2,000
Q3 2022

Nov 14, 2022

BUY
$6.12 - $9.5 $140 - $218
23 Added 26.74%
109 $1,000
Q2 2022

Aug 12, 2022

SELL
$4.7 - $7.22 $298,901 - $459,163
-63,596 Reduced 99.86%
86 $0
Q1 2022

May 16, 2022

BUY
$5.62 - $12.37 $4,805 - $10,576
855 Added 1.36%
63,682 $382,000
Q4 2021

Feb 14, 2022

SELL
$10.65 - $18.61 $2.65 Million - $4.62 Million
-248,370 Reduced 79.81%
62,827 $769,000
Q3 2021

Nov 15, 2021

SELL
$14.65 - $26.07 $704,108 - $1.25 Million
-48,062 Reduced 13.38%
311,197 $5.15 Million
Q2 2021

Aug 16, 2021

BUY
$28.0 - $28.0 $10.1 Million - $10.1 Million
359,259 New
359,259 $10.1 Million

Others Institutions Holding CVRX

About CVRx, Inc.


  • Ticker CVRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 20,576,200
  • Market Cap $278M
  • Description
  • CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure (HF) with reduced ejection fraction or systolic HF. The co...
More about CVRX
Track This Portfolio

Track Wells Fargo & Company Portfolio

Follow Wells Fargo & Company and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.